Skip to main content
SpringerLink
Log in

Ethical aspects of the safety of medicines and other social chemicals

  • Published:
Science and Engineering Ethics Aims and scope Submit manuscript

Abstract

The historical background of the discovery of adverse health effects of medicines, food additives, pesticides, and other chemicals is reviewed, and the development of national and international regulations and testing procedures to protect the public against the toxic effects of these drugs and chemicals is outlined. Ethical considerations of the safety evaluation of drugs and chemicals by human experimentation and animal toxicity studies, ethical problems associated with clinical trials, with the falsification of clinical and toxicological data, and with inadequate experimental methodology, are reviewed, and the ethics of the marketing of drugs and their post-marketing surveillance, are similarly considered. These ethical problems are illustrated with many specific examples, including the drugs neoarsphenamine, chloramphenicol, thalidomide, diethyl stilboestrol and benoxaprofen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Albert A (1985)Selective Toxicity. 7th edition, Chapman and Hall, London.

    Book  Google Scholar 

  2. Parke D V (1986)The Biochemistry of Foreign Compounds. Pergamon, Oxford.

    Google Scholar 

  3. Liu P T, Ioannides C, Symons A M & Parke D V (1993) Role of tissue glutathione in prevention of surgical trauma.Xenobiotica,23: 899–911.

    Article  Google Scholar 

  4. Larsson A, Orrenius S, Holmgren H & Mannervik B (1983)Functions of Glutathione: Biochemical, Physiological, Toxicological and Clinical Aspects. Raven, New York.

    Google Scholar 

  5. Parke D V (1994) Clinical pharmacokinetics in drug safety evaluation.ATLA 22: 207–209.

    Google Scholar 

  6. Parke D V (1985) Adverse effects of drugs — their causes and prevention.Journal of the Royal Society of Health,105: 39–46.

    Article  Google Scholar 

  7. Lischner H, Seligman JS, Krammer A & Parmelee AH Jr. (1961) An outbreak of neonatal deaths among term infants associated with administration of chloramphenicol.Journal of Pediatrics,59: 21–25.

    Article  Google Scholar 

  8. Parke D V (1974) Drugs in pregnancy and lactation, In: Curry AS & Hewitt JV, eds.Biochemistry of Women: Clinical Concepts. CRC Press, Cleveland, Ohio: 111–136.

    Google Scholar 

  9. Sjöström H and Nilsson R. (1972)Thalidomide and the Power of the Drug Companies, Penguin Books, Harmondsworth, England.

    Google Scholar 

  10. Parke D V (1984) Development of detoxication mechanisms in the neonate, In: S Kacew & MJ Reasor eds,Toxicology and the Newborn, Elsevier, Amsterdam: 11–32.

    Google Scholar 

  11. Lenz W & Knapp K (1962) Thalidomide embryopathy,Archives of Environmental Health,5: 100–105.

    Article  Google Scholar 

  12. Herbst A L, Ulfelder H & Poskanzer D C (1971) Adenocarcinoma of the vagina — association of maternal stilboestrol with tumour appearance in young women.New England Journal of Medicine,284: 878–881.

    Article  Google Scholar 

  13. Greenwald, P, Barlow J J, Nasca P C & Burnett W S. (1971) Vaginal cancer after maternal treatment with oestrogens.New England Journal of Medicine,285: 390–393.

    Article  Google Scholar 

  14. WHO (1958) Procedures for the testing of intentional food additives to establish their safety for use — Second Report of the Joint FAO/WHO Expert Committee on Food Additivies. Technical Report Series, No.144: 19pp.

  15. National Academy of Sciences (1960) Problems in the evaluation of carcinogenic hazard from use of food additives. Washington, National Research Council. Publication No. 479.

  16. Vettorazi G (1975) Toxicological decisions and recommendations resulting from the safety assessment of pesticide residues in food.Critical Reviews in Toxicology 4: 125–183.

    Google Scholar 

  17. Parke D V (1977) Toxic chemicals in food.Journal of Forensic Science,16: 189–191.

    Article  Google Scholar 

  18. Frazer A C & Sharratt M (1969) The value and limitations of animal studies in the prediction of effects in man. In:The use of animals in toxicological studies UFAW Symposium, England, 1968, England, 41 pp.

  19. Barnes J M (1960) Toxicity testing. In: Schilling RSF ed.Modern trends in occupational health. Butterworths, London: pp 20–32.

    Google Scholar 

  20. Eason C T, Clark B, Smith D A & Parke D V (1982) The mechanism of hepatotoxicity of a chromone carboxylic acid (FPL 52727) in the dog,Xenobiotica,12: 155–164.

    Article  Google Scholar 

  21. Parke D V & Ioannides C (1990) Role of cytochromes P450 in mouse liver tumor production. in: Ed. Stevenson D E, McClain R M, Popp J A, Slaga T J, Ward J M & Pitot H C,Mouse Liver Carcinogenesis. Mechanisms and Species Comparisons, Alan R. Liss, New York: 215–230.

    Google Scholar 

  22. Williams R T (1959)Detoxication mechanisms – The metabolism and detoxication of drugs, toxic substances, and other organic compounds. Chapman & Hall, London.

    Google Scholar 

  23. Parke D V (1983) Species differences in pharmacokinetics,Veterinary Research Communications,7, 285–300.

    Article  Google Scholar 

  24. Berry D J, Webley M, Grahame R, Goulding R, Gaetani M & Parke D V (1993) Pharmacokinetics of single oral doses of feprazone in patients with rheumatoid arthritis or with impaired renal clearance.Xenobiotica,23: 1231–1240.

    Article  Google Scholar 

  25. Shah R R (1993) Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.Xenobiotica,23: 1159–1194.

    Article  Google Scholar 

  26. Parke D V & Aherne G W (1982) Approval of anticancer drugs for use in general medical practice. Pp. 93–101. In: Hilgard P & Hellman K, ed.Anticancer Drug Development. First International Symposium on Management and Realisation of Anticancer Drug Development, Prous SA, Barcelona.

    Google Scholar 

  27. Lewis D F V, Ioannides C & Parke D V (1991) A retrospective study of the molecular toxicology of benoxaprofen,Toxicology,65: 33–47.

    Article  Google Scholar 

  28. Neuberger J & Williams R (1989) Immune mechanisms in tienilic acid - associated hepatotoxicity,Gut,30: 515–519.

    Article  Google Scholar 

  29. Hyde R, Smith J N & Ioannides C (1987) Induction of hepatic mixed-function oxidases by Arochlor 1254 in the hamster: comparison of Arochlor-induced rat and hamster preparations in the activation of pre-carcinogens in the Ames test,Mutagenesis,2: 477–482.

    Article  Google Scholar 

  30. U.S. FDA (1978) Good laboratory practice regulations,Federal Register 43: 49986–60020.

    Google Scholar 

  31. U.S. EPA (1983) Good laboratory practice standards: Toxicity testing.Federal Register 48: 53922.

    Google Scholar 

  32. Rawlins MW (1984) Postmarketing surveillance of adverse reactions to drugs,British Medical Journal,288: 879–880.

    Article  Google Scholar 

  33. Brantom P (1983) Dose-response relationships in nitrosamine carcinogenesis, PhD Thesis, University of Surrey.

  34. Haverkos H W, Kopste A N, Wilson H and Drotman D P (1994) Nitrite inhalants: History, epidemiology and possible link to AIDS.Environmental Health Perspectives,102: 858–861.

    Article  Google Scholar 

  35. WHO (1990) Environmental Health Criteria 104. Principles for the toxicological assessment of pesticide residues in food. Geneva.

Download references

Author information

Authors and Affiliations

  1. Division of Molecular Toxicology, School of Biological Sciences, University of Surrey, GU2 5XH, Guildford, Surrey, UK

    Dennis V. Parke

Authors
  1. Dennis V. Parke
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Parke, D.V. Ethical aspects of the safety of medicines and other social chemicals. Sci Eng Ethics 1, 283–298 (1995). https://doi.org/10.1007/BF02628804

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02628804

Keywords

Search

Navigation